Published in AIDS Weekly, July 22nd, 2002
William R. Robinson and colleagues at Texas Tech University's Harrington Cancer Center in Amarillo evaluated isotretinoin's ability to prevent low-grade, benign cervical lesions from progressing to high-grade or malignant lesions during HIV infection.
Although the researchers did uncover some good news for HIV+ women, they also found that isotretinoin failed to provide them with significant protection from cervical lesion progression.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.